β-Cell Regeneration via HIF1α-PFKFB3 Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a progressive decline in β-cell function in type-2 diabetes (T2D) due to the accumulation of toxic oligomers of islet amyloid pancreatic polypeptide (IAPP), leading to dysfunctional β-cells that are unable to regenerate effectively, despite extensive research on methods to induce elimination of damaged cells and regeneration of healthy cells.
Innovation Solution
Inhibition of HIF1α activity, potentially combined with PFKFB3 inhibition, to facilitate β-cell regeneration by promoting the elimination of damaged cells and enhancing the regeneration of healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HIF1α and PFKFB3 pathways are inhibited, then damaged β-cells are eliminated and healthy β-cells regenerate, but the treatment complexity increases
Solution Approach 1:
The patent combines inhibition of HIF1α and PFKFB3 pathways into a unified treatment approach to achieve β-cell regeneration. By merging these two inhibitory mechanisms, the patent creates a synergistic effect that promotes the elimination of damaged β-cells and regeneration of healthy ones, while managing treatment complexity through integrated therapy design.
Solution Approach 2:
The patent employs parameter changes by modulating the activity levels of HIF1α and PFKFB3 pathways. Through pharmacological intervention, the patent alters the expression and activity parameters of these pathways to transition β-cells from a damaged state to a regenerating state, thereby improving β-cell function and mass.
2Quantity of substance
If β-cell mass is preserved, then tissue structure is maintained, but β-cell function is lost due to dysfunction
Solution Approach 1:
The patent extracts and eliminates the dysfunctional portion of the β-cell population through targeted apoptosis induction. By removing the non-functional β-cells that accumulate in T2D, the patent preserves the structural integrity of the pancreatic islets while regenerating functional β-cells, thereby resolving the contradiction between maintaining β-cell mass and preserving β-cell function.
Solution Approach 2:
The patent discards damaged β-cells through programmed cell death while recovering and regenerating healthy β-cells. This process of selective elimination followed by regeneration restores functional β-cell mass, transforming the dysfunctional tissue state into a functional state while maintaining overall tissue structure.
Data Source
AI summary
Aspects of the present disclosure are directed to methods and compositions for facilitating β-cell regeneration by inhibition of the HIF1α-PFKFB3 pathway. Certain aspects describe methods for treatment and prevention of prediabetes and diabetes, including type 2 diabetes. Also disclosed are methods and compositions for enhancing β-cell regeneration.